Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.
Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.
The results of a univariate analysis have shown that the presence of hyperdiploidy and chromosomal aberrations del(17p13), t(4;14), and +1q21 are all associated with shorter time to progression from smoldering multiple myeloma to active disease.
Researchers have helped to better define the spectrum of light chain (AL) amyloidosis by identifying that AL amyloidosis patients with myeloma who have more than 10% bone marrow plasma cells or those with hypercalcemia, renal failure, anemia, and lytic bone lesions have a similar prognosis to patients with overt myeloma.
Adding vorinostat to bortezomib for the treatment of relapsed multiple myeloma resulted in a statistically significant increase in progression-free survival compared with bortezomib alone, according to results of a new study.
The addition of the oral pan-deacetylase inhibitor panobinostat to bortezomib helped to elicit responses in about one-third of heavily pre-treated patients with multiple myeloma who were refractory of bortezomib, according to the phase II results of the PANORAMA 2 study.
Pomalidomide, an immunomodulatory drug, combined with low-dose dexamethasone improved progression-free survival in patients with refractory or relapsed and refractory multiple myeloma compared with standard of care high-dose dexamethasone, according to a new study.
Myelomas that “lack” a monoclonal protein can be divided further into those that produce some protein and yet do not secrete it or whose serum concentration is so low that it cannot be measured, and those that truly produce no monoclonal protein at all.
In this interview we discuss the current management and latest treatments and agents in development for multiple myeloma with Dr. Kenneth Anderson of the Dana-Farber Cancer Institute.
Today we speak with Steven T. Rosen, MD, about a couple of the projects he and his group are working on, repurposing old drugs for the treatment of multiple myeloma, that will be presented this year at ASH.
